| ²é¿´: 1256 | »Ø¸´: 2 | |||
dylfgsľ³æ (ÖøÃûдÊÖ)
ÖÐÀɽ«
|
[½»Á÷]
0.01% w/v of simvastatin BPCRS in solution A.
|
|
ÇëÎÊ£º2013°æBPÖжÔÐÁ·¥Ëû͡ƬµÄÒªÇóÖУ¬ÓйØÎïÖʵIJⶨÖУ¬ÓÐÈçÏ¡°Mobile phase A 50 volumes of acetonitrile and 50 volumes of a 0.1% v/v solution of orthophosphoric acid . (2) 0.01% w/v of simvastatin BPCRS in solution A. (3) 0.002% w/v of each of simvastatin BPCRS and lovastatin EPCRS. (4) 0.1% w/v of simvastatin for peak identification EPCRS. ¡±£¨2(3)(4)ÖеÄÃèÊöÊÇÉñÃÅÒâ˼£¬Êǽ«simvastatin BPCRS ÈÜÓÚsolution AÖУ¬ÅäÖÆ³É0.01%µÄÈÜÒºÂ𣿠½«simvastatin BPCRS and lovastatin EPCRS.ÅäÖÆ³É0.002%µÄÈÜÒº£¬ ½« simvastatin for peak identification EPCRSÅäÖÆ³É0.1%µÄÈÜÒºÂ𣿠Çë´ó¼Ò·¢±í×Ô¼ºµÄ¼û½â£¬Ð»Ð»£¬¸Ð¼¤ÌéÁã |
» ²ÂÄãϲ»¶
¹òÇóÒ»Ö§AAV293ϸ°û
ÒѾÓÐ1È˻ظ´
͸Ã÷ÖÊËá ¼×»ù±ûÏ©Ëáôû
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ173È˻ظ´
305²ÄÁÏר˶µ÷¼Á
ÒѾÓÐ12È˻ظ´
CSC¸ÄÅÉ-²©Ê¿Éú½»Á÷·Ãѧ
ÒѾÓÐ19È˻ظ´
ÖÐɽ´óѧ-µÚÆßÒ½Ôº-ÕпÆÑÐÖúÀí1Ãû£¨»ùÒòÉè¼ÆºÍ¿Ë¡¡¢RNAºÏ³É£©
ÒѾÓÐ0È˻ظ´
ÖÐɽ´óѧ-µÚÆßÒ½Ôº-ÕпÆÑÐÖúÀí1Ãû£¨»ùÒòÉè¼ÆºÍ¿Ë¡¡¢RNAºÏ³É£©
ÒѾÓÐ1È˻ظ´
°ÍÀèÈø¿ËÀ×´óѧÓë¹ú¼ÒÁôѧ»ù½ðίºÏ×÷²©Ê¿Ñо¿ÉúÏîÄ¿-Ö¬ÖÊÄÉÃ×Ò©Îï/ÉúÎï²ÄÁÏ/¶à·ÓµÝËÍ
ÒѾÓÐ10È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ0È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ2È˻ظ´
26É격×Ô¼ö
ÒѾÓÐ12È˻ظ´

2Â¥2015-07-29 16:46:57
dylfgs
ľ³æ (ÖøÃûдÊÖ)
ÖÐÀɽ«
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 9823.7
- É¢½ð: 135
- ºì»¨: 6
- Ìû×Ó: 1263
- ÔÚÏß: 321.7Сʱ
- ³æºÅ: 1028007
- ×¢²á: 2010-05-25
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö

3Â¥2015-07-30 10:35:17














»Ø¸´´ËÂ¥